29 August, 2023 | Comments Off on Blocking multi-neuronal sensitization effects of IL-4 and IL-13 through Interleukin-13 receptor alpha 1 (IL-13Rα1) with eblasakimab
29 August, 2023 | Comments Off on Eblasakimab Improves Itch and Sleep Loss in Adult Patients with Moderate-to-severe Atopic Dermatitis in a Randomized, Double-blinded, Placebo-controlled, Phase 1 Study
29 August, 2023 | Comments Off on Eblasakimab, a Monoclonal Antibody Targeting IL‑13Rα1 Reduces Serum Biomarkers Associated with Atopy and Correlated with Disease Severity in Patients With Moderate‑to‑Severe Atopic Dermatitis
19 June, 2023 | Comments Off on Eblasakimab, a novel IL-13 receptor alpha 1 monoclonal antibody, blocks STAT6 phosphorylation with low dose in human volunteers
17 May, 2023 | Comments Off on Eblasakimab monotherapy improves moderate-to-severe atopic dermatitis symptoms across anatomical regions in a Phase 1 study
18 April, 2023 | Comments Off on Insight into novel itch pathways and spontaneous neuronal activity by targeting interleukin 13 receptor alpha 1 (IL13Rα1) with eblasakimab
